Background
Head and neck squamous cell carcinoma (HNSCC), which includes cancer of the oral cavity, nasal/sinonasal cavity, pharynx, and larynx, is the sixth most common cancer type worldwide, with little improvement in prognosis over the last few decades [1]. The first-line therapies for patients with advanced HNSCC are surgery and platinum-based chemoradiotherapy, both of which cause severe toxicity [2]. Despite initial treatment, several patients with HNSCC succumb to the disease due to recurrence or metastasis [3]. Cancer immunotherapy, including immune checkpoint inhibitors (ICIs), is a promising strategy to treat otherwise untreatable cancers, including HNSCC [4,5]. By blocking the interaction of negative immune checkpoint molecules with their ligands, the immune checkpoint blockade potentiates antitumor immune cells, followed by substantial antitumor responses. However, only 20% of the patients could receive the clinical benefits from ICI monotherapy [6,7]. Several clinical studies have shown that combination therapy with ICIs and cytotoxic chemotherapy (immunochemotherapy) is promising for the treatment of advanced cancer [8,9]. The spread of tumor epitopes through cytotoxic chemotherapy can augment antitumor T-cell stimulation by ICIs. Recently, pembrolizumab plus platinum and 5-fluorouracil chemotherapy have shown high clinical efficiency with acceptable safety compared to standard treatments (e.g., cetuximab plus platinum-based chemotherapy) in HNSCC [10]. Accordingly, the
combination of ICI and platinum-based chemotherapy has become the first-line treatment for recurrent or metastatic HNSCC. ICIs can induce autoimmune diseases, such as immune-related adverse events (irAEs) by disrupting the immune homeostasis [11]. Steroids are typically administered to treat irAEs, which damage the lungs, liver, colon, pancreas, and skin [12,13]. However, immunosuppressive drugs, including steroids, could be disadvantageous for cancer immunotherapy. Several clinical studies have shown that steroid use impeded the antitumor effect of ICI treatment [14–16]. In some clinical trials, the patients treated with corticosteroids were excluded from the ICI treatment [17]. Since patients undergoing platinum-based chemotherapy, such as cisplatin (CDDP), a key drug for the treatment of HNSCC, often receive dexamethasone to prevent severe nausea, no consensus has been reached as to how steroids influence the antitumor activity of ICIs combined with CDDP. Therefore, preclinical examination is necessary to determine whether steroids reduce the antitumor effect of T cell-based immunotherapy on HNSCC in vivo and in vitro. Additionally, we showed that IL-2 restored the steroid-derived dysfunction of antigen-specific T cells in vitro, and IL-2/anti-IL-2 complexes (IL-2 Cx) recovered immune inhibition of steroids in an HNSCC mouse model treated with immunotherapy.

**Materials and methods**

**Cell line and mice**

HSC4 (tongue SCC) was supplied by the RIKEN BioResource Center (Tsukuba, Ibaraki, Japan). HPC-92Y (hypopharyngeal SCC) was kindly provided by Dr. Syunsuke Yanoma (Yokohama Tsurugamine Hospital, Yokohama, Japan). MOC1 (tongue SCC derived from C57BL/6 mice) was supplied by Kerafast Inc. (Boston, MA, USA). All cell lines were maintained by tissue culture with RPMI1640 (Nacalai tesque, Japan), 10% FBS (Sigma-Aldrich, Burlington, MA, USA), and Penicillin-Streptomycin (Gibco, Waltham, MA, USA). All cell lines were used within 10 passage after obtaining from the distributors. C57BL/6 mice (female, 8 to 10 weeks old) were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). All the mice were maintained in a specific pathogen-free facility at the Asahikawa Medical University. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Asahikawa Medical University (#20001).

**In vitro proliferation and survival assay of antigen-specific CD4+ T cells**

The induction of EGFR<sub>875-889</sub>-specific CD4<sup>+</sup> helper T lymphocytes (HTLs) has been previously described in detail [18]. Briefly, purified HTLs were stimulated weekly with EGFR<sub>875-889</sub> peptide, and peptide-specific T cells were selected by limiting dilution. The
proliferation of T cells and HNSCC cell lines in response to dexamethasone was investigated using the MTS assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega, Madison, WI). The tumor cells (HSC4 or HPC-92Y) and EGFR875-889-specific HTLs (T8) [18] were seeded in a 96-well culture plate and treated with dexa-
methasone (0–300 µg/mL) for 24 h. After incubation with MTS solution for 1 h, the absorption was measured at 490 nm using a GloMax Discover Microplate Reader (Promega, Madison, WI).

Characterization of antigen-specific CD4+ T cells

EGFR875-889-specific HTLs (T8) were treated with dexamethasone (0, 0.3, and 3 µg/mL) for 24 h, and stained with APC-conjugated anti-PD-1 (EH12.2H7) monoclonal antibody (mAb), PerCP-conjugated anti-LAG-3 (11C3G65) mAb, APC-conjugated anti-TIM3 (F38–2E2) mAb, APC/Cy7-conjugated anti-CD62L (DREG-56), PE-conjugated anti-CD44 (B718) mAb, and isotype monochonal mAb. All the antibodies used for flow cytometric analysis were obtained from BioLegend. All the samples were analyzed using a CytoFLEX flow cytometer and CytExpert (Beckman Coulter).

In vitro antigen recognition and anti-tumor effect of CD4+ T cells

EGFR875-889-specific HTLs (T8, 1 × 10⁵) were co-cultured in 96-well culture plate with EGFR875-889 peptide-loaded antigen-presenting cells (APCs: γ-irradiated autologous PBMCs, 1 × 10⁵) or HLA-DR-matched tumor cell lines (3 × 10⁴) in the presence of dexamethasone (0–30 µg/mL) for 24 h. The tumor cell lines used in this study expressed EGFR, as described previously [18]. The supernatants were collected and evaluated for IFN-γ by ELISA (BD Pharmingen, San Diego, CA, USA) according to the manufacturer’s instructions. To examine the timing of steroid treatment, T8 cells were pretreated with dexamethasone (Pre-Dex) for 48 h before co-culture, as indicated in the figure. In the killing assay, the tumor cell lines were labeled using the CellTrace™ CFSE Cell Proliferation Kit (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) 6 h before co-culturing with several effector/target cell (E: T) ratios of T cells. The dead cells were assessed by flow cytometry (CytoFLEX

Fig. 2. Immune cell population analysis of spleens, tumor-draining lymph nodes, and tumor infiltrating lymphocytes. Immune cells from the spleen, tumor-draining lymph nodes (dLNs), and tumor-infiltrating lymphocytes (TILs) were harvested on day 45 after MOC1 inoculation. Each group was treated as shown in Fig. 1. (A) The percentage of CD4+ T cells, CD8+ T cells, and Gr-1+ cells in spleens, dLNs, and TILs. (B) The percentage of CD44+ CD62L+ or CD44− CD62L− in CD8+ T cells in spleens, dLNs, and TILs. (C) The percentage of CD44+ CD62L+ or CD44− CD62L− in CD8+ T cells in spleens, dLNs, and TILs. (D) The percentage of PD-1+ in CD4+ or CD8+ T cells in spleens, dLNs, and TILs. Bars and error bars indicate the mean and SD, respectively (*p<0.05, **p<0.01, Student’s t-test).
flow cytometer, Beckman Coulter) using 7-AAD viability staining solution (BioLegend).

In some experiments, the T8 cells were cultured without dexamethasone for 5–10 days or co-cultured with IL-2 (100 U/ml) after treatment with dexamethasone (0.3 or 3 µg/mL); additionally, the peptide reactivity was evaluated using IFN-γ ELISA.

**In vivo steroid treatment and tumor assessment**

C57BL/6 mice were intradermally injected with MOC1 (1 × 10⁶). The mice were intraperitoneally administered CDDP (6 mg/kg) on days 18, 25, and 32 after tumor inoculation. In the indicated group, anti-PD-1 Ab (200 µg/mouse) and dexamethasone (1 mg/kg) were intraperitoneally administered three times per week and three sequential days with CDDP administration, respectively. To assess the effect of IL-2 on steroids, IL-2 Cx was intraperitoneally administered three times every two days for one cycle from day 18. IL-2 Cx was prepared by mixing IL-2 (BioLegend) and IL-2 mAb (JES6–5H4, BioXcell), which has a high affinity for IL-2 receptor β chain (CD122), and incubating the complexes overnight at 4 °C. Tumor growth was monitored every 2–3 days. The results are presented as the mean tumor size (mm²) with SD.

The surface markers of immune cells in the spleen, tumor-draining lymph nodes (dLNs), and tumor-infiltrating lymphocytes (TILs) were assessed on day 45. The TILs were disaggregated from tumor tissues using collagenase (1 mg/ml) and gentMACS (Miltenyi Biotec, Berguch, Germany) according to the manufacturer’s instructions. The immune cells were stained with APC-conjugated anti-I-A-I-E (M5/114.15.2) mAb, PerCP-conjugated anti-CD4 (GK1.5) mAb, APC/Cy7-conjugated anti-CD8a (53–6.7) mAb, FITC-conjugated anti-CD62L (MEL-14) mAb, PC-7-conjugated anti-CD44 (IM7) mAb, PE-conjugated anti-PD-1 (29F.1A12) mAb, PCS.5-conjugated anti-NK-1.1 (PK136) mAb, APC/A750-conjugated anti-GR-1 (RB6–8C5) mAb, and the isotype monoclonal mAb. All the antibodies used for flow cytometric analysis were obtained from BioLegend. All samples were analyzed using a CytoFLEX flow cytometer and software (Beckman Coulter).

**Statistical analysis**

The statistical differences between groups were determined using the Student’s t-test and one-way ANOVA with Tukey’s method (GraphPad Prism 8). The statistical significance was set at p < 0.05.

**Results**

**Steroid inhibits the effect of PD-1 blockade with chemotherapy in vivo**

Since steroids are frequently used in clinics to relieve nausea with high-risk emetic chemotherapy including CDDP-combined PD-1 blockade, we evaluated whether immunosuppression by dexamethasone inhibits the anti-tumor effects of immunochemotherapy in a mouse model. The combination therapy consisted of CDDP and anti PD-1 (29F.1A12) mAb, PCS.5-conjugated anti-NK-1.1 (PK136) mAb, APC/A750-conjugated anti-GR-1 (RB6–8C5) mAb, and the isotype monoclonal mAb. All the antibodies used for flow cytometric analysis were obtained from BioLegend. All samples were analyzed using a CytoFLEX flow cytometer and software (Beckman Coulter).
significantly reduced the percentage of CD4+ T cells and CD8+ T cells in spleens, dLNs, and TILs, irrespective of immunochemotherapy. In addition, NK cells also decreased following steroid treatment (Supplementary Fig. 2). In contrast, the percentage of Gr-1+ myeloid cells increased with steroid treatment in the spleen. Notably, the percentage of both CD44+ CD62L+ (effector memory) and CD44+ CD62L+ (central memory) subsets in CD4+ and CD8+ T cells was reduced by dexamethasone in all the samples (Fig. 2 B and C). The reduction of both effector and memory cells in PBMCs was found one week after treatment (Supplemental Fig. 3), indicating that steroids inhibit immune cells within the early period of treatment. The percentage of PD-1+ T cells was not affected by the steroids (Fig. 2D). These results suggest that steroids might inhibit antitumor immunity by reducing central memory and effector memory subsets, in addition to total CD4+ T cells and CD8+ T cells.

Dexamethasone regulates survival and proliferation of antigen-specific T cells in vitro

Several studies have shown that steroids lead to the apoptosis of T cells [19]. Because T cell epitopes have not been identified in the mouse HNSCC model, we used EGFR-specific CD4+ helper T lymphocyte (HTLs) clones from human PBMCs [18] to further elucidate the effects of steroid in tumor antigen-specific T cells. Being widely expressed in HNSCC, EGFR is selected as a model tumor antigen. HNSCC cell lines (HPC-92Y and HSC4) expressed EGFR, which remained stable with dexamethasone (Supplementary Fig. 4). After co-culturing with EGFR875–889-reactive HTLs (T8), dexamethasone reduced the proliferation of EGFR875–889-reactive HTLs in a dose-dependent manner (Fig. 3 A). The proliferation of tumor cell lines (HPC-92Y and HSC4) was not affected by dexamethasone. Similar to the proliferation, the survival of T cells was directly impeded by dexamethasone in a dose-dependent manner, whereas the tumor cells were not affected (Fig. 3 B). PD-1, LAG-3, and TIM-3 are negative immune checkpoints expressed on exhausted T cells. In addition to the in vivo model (Fig. 2 C), both the CD44+ CD62L+ (effector memory) and CD44+ CD62L+ (central memory) cells in EGFR875–889-reactive HTLs were also decreased by dexamethasone (Fig. 3 D). Altogether, steroid-induced apoptosis, the limited proliferation of antigen-specific CD4+ T cells, and reduced memory T cell proportion without upregulating inhibitory checkpoints.
Fig. 4. Direct recognition and anti-tumor effect by EGFR<sub>875–889</sub>-reactive HTLs with dexamethasone; (A) T<sub>8</sub> were evaluated for IFN-γ production with EGFR<sub>875–889</sub> peptide (3 µg/ml) and various concentration of dexamethasone in the context of autologous PBMCs as APCs. (B) Direct tumor recognition by T<sub>8</sub> with various concentration of dexamethasone was evaluated by co-culturing T cells and tumor cell lines (HPC-92Y and HSC4). IFN-γ production was used as an output. (C, D) T<sub>8</sub> were co-cultured with various concentration of dexamethasone for 48 h and washed with PBS. Subsequently, IFN-γ production of steroid-pretreated T<sub>8</sub> in the context of (C) peptide-pulsed γ-irradiated autologous PBMCs or (D) tumor cell lines (HPC-92Y and HSC4) was evaluated. (E) T<sub>8</sub> were concurrently (Dex) or pre-treated for 48 h (Pre-Dex) with dexamethasone (3 µg/mL), and evaluated for IFN-γ production with tumor cell lines. (F) Tumoricidal ability of T<sub>8</sub> with concurrently (Dex) or pre-treated for 48 h (Pre-Dex) with dexamethasone (3 µg/mL). T<sub>8</sub> was co-cultured with CSFE-labeled tumor cell lines (HPC-92Y and HSC4) for 6 h with several E: T (Effector: Target cells) ratio, and evaluated the percentages of dead tumor cells (CFSE<sup>+</sup>7-AAD<sup>+</sup> cells) with flow cytometry. Symbols and error bars indicate the mean and SD, respectively. Experiments were performed in triplicate. (*<i>p</i><0.05, **<i>p</i><0.01, ***<i>p</i><0.001, Student’s t-test).

Fig. 5. IL-2 recovers the function of EGFR-reactive HTLs impaired by dexamethasone; EGFR<sub>875–889</sub>-specific HTLs (T<sub>8</sub>) were co-cultured with dexamethasone (3 µg/mL) for 48 h and washed with PBS. (A) Pre-treated T<sub>8</sub> cells were rested for 5 or 10 days, and IFN-γ production in tumor cells was evaluated by ELISA. (B) Pre-treated T<sub>8</sub> cells were co-cultured with various concentration of IL-2 (10 U/ml or 100 U/ml) for 48 h after washing, and the percentage of CD44<sup>+</sup>CD62L<sup>+</sup> or CD44<sup>+</sup>CD62L<sup>+</sup> in T<sub>8</sub> cells was evaluated by flow cytometry.

### Additional Information

- **Translational Oncology** 18 (2022) 101358
- **M. Kono et al.**
- **Graphical Abstract:**
  - **Fig. 4:** Direct recognition and anti-tumor effect by EGFR<sub>875–889</sub>-reactive HTLs with dexamethasone.
  - **Fig. 5:** IL-2 recovers the function of EGFR-reactive HTLs impaired by dexamethasone.
Dexamethasone inhibits anti-tumor effect of antigen-specific T cells in vitro

To evaluate the functional regulation of HTLs by steroids, EGFR<sup>875–889</sup>-reactive HTLs (T8) were co-cultured with peptide-pulsed autologous PBMCs or EGFR-expressing HLA-DR-matched HNSCC cell lines in the presence of dexamethasone. As shown in Fig. 4 A, IFN-γ production in T8 cells co-cultured with EGFR<sup>875–889</sup>-peptide-pulsed γ-irradiated autologous PBMCs was attenuated by dexamethasone in a dose-dependent manner. The IFN-γ production in T8 cells co-cultured with tumor cell lines was also reduced by dexamethasone (Fig. 4 B). To examine whether the reduction of IFN-γ production from T cells requires concurrent culture with steroids and APCs, T8 cells were pre-treated with dexamethasone (0–30 µg/mL) for 48 h and washed with PBS. As shown in Fig. 4 C and D, pretreatment with dexamethasone reduced the production of IFN-γ from T8 against γ-irradiated autologous PBMCs or tumor cell lines. The IFN-γ production was equally suppressed in T8 cells treated with concurrent or pre-dexamethasone (Fig. 4 E). These results suggest that steroids can directly diminish the antigen reactivity and cytotoxicity of tumor-reactive HTLs, irrespective of the presence of APCs.

IL-2 recovers antigen reactivity of steroid-induced anergic T cells

Subsequently, we investigated whether the reduced antigen reactivity of HTLs by dexamethasone was recovered by resting or adding cytokines. As shown in Fig. 5 A, IFN-γ production from HTLs was not recovered by resting for 5 to 10 days after co-culturing with dexamethasone. In contrast, steroid-induced anergic HTLs recovered IFN-γ production in tumor cells with IL-2 supplementation (Fig. 5 B). The proportion of memory T cells reduced by steroids was also recovered by 100 U/ml IL-2 (Fig. 5 C). These results indicate that the steroid-induced suppression of antitumor T cells can be recovered by IL-2.

IL-2 complex recovers antitumor effect of immunochemotherapy impaired by steroid in HNSCC mouse model

To assess whether IL-2 restores the immunosuppression of antitumor T cells by steroids in vivo, IL-2 Cx was added to the immunochemotherapy/steroid mouse model (Fig. 6 A). As shown in Fig. 6 B, IL-2 Cx significantly diminished the negative effects of dexamethasone in the immunochemotherapy model. The percentage of CD4<sup>+</sup> and CD8<sup>+</sup> T cells decreased by dexamethasone in the spleen, dLNs, and TILs was restored by IL-2 Cx. The percentage of Gr-1<sup>+</sup> myeloid cells was not affected by the IL-2 Cx treatment. Moreover, the percentages of both CD44<sup>+</sup>CD62L<sup>+</sup> (effector memory) and CD44<sup>+</sup>CD62L<sup>+</sup> (central memory) subsets in CD4<sup>+</sup> and CD8<sup>+</sup> T cells were also recovered to the extent of the non-steroid group by IL-2 Cx (Fig. 7 B and C). The recovery of T cells from steroids was observed during the early period of treatment (Supplementary Fig. 5). In addition, the number of NK cells, which was downregulated by steroids, was also recovered with IL-2 Cx (Supplementary Fig. 6). Collectively, these data demonstrate that IL-2 Cx recovered the antitumor effect of immunochemotherapy suppressed by dexamethasone by restoring the number of total CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, memory T cells, and NK cells. IL-2 is a potent immune adjuvant that activates antitumor T cells during immunchemotherapy with steroids.
Discussion

To the best of our knowledge, there have been no reports regarding the effects of steroids on ICIs combined with chemotherapy in clinical or preclinical models of HNSCC. In this study, we showed that dexamethasone caused immunosuppression and tumor growth inhibition in an HNSCC mouse model treated with PD-1 blockade and CDDP. In other types of cancer, several reports indicate that steroids have adverse effects on patients undergoing ICIs. Corticosteroids have been associated with poor prognosis in non-small-cell lung cancer patients treated with anti-PD-(L)1 antibody (Ab) [14,20]. In patients with glioblastoma receiving anti-PD-(L)1 Ab therapy, the baseline use of dexamethasone attenuated the overall survival [21]. Tallon de Lara et al. showed that the addition of dexamethasone to ICIs with gemcitabine resulted in a synergistic clinical response [22]. The induction of IFN-γ responses to personalized neoantigen-targeting vaccines was also inhibited by dexamethasone [23]. Conversely, some studies have suggested that steroids have no significant impact on the efficacy of ICIs. In hepatocellular carcinoma, corticosteroid therapy did not influence the response rate or overall survival following ICIs [24]. Jeffrey et al. showed that corticosteroid use did not affect the overall response rate in advanced melanoma with nivolumab monotherapy [25]. However, these patients received corticosteroids due to irAEs, which is associated with improved survival in the patients treated with ICIs [26]. Thus, steroids are likely to have adverse effects on cancer immunotherapy; however, the direct association between steroids and treatment responses to ICIs remains to be elucidated in the clinic.

In general, steroids attenuate T cell activation, differentiation, migration, and cytokine production with increasing regulatory T cells [19,27]. Our results show that steroids suppress effector memory T cells and central memory CD4+ T cells and CD8+ T cells both of which play essential roles in ICIs [28] [29]. The impediment of CD28-mediated cell
cycle entry and CTLA-4 induction by steroids might inhibit the differentiation of naïve T cells into these two essential subsets [30]. Since steroid inhibits the migration of T cells, the number of periphery T cells was inhibited in addition to lymph tissues and tumor-infiltrating cells. Thus, lymphocyte migration might be indispensable for the inhibition of antitumor T cell responses by dexamethasone in the anti-PD1 therapy model. Moreover, we showed that dexamethasone decreased the NK cells, which can kill tumor cells through antibody-dependent cytotoxic activity [31]. Steroids not only suppress T cells and NK cells, but also stimulate M2 macrophage skewing [32], and inhibit dendritic cells proliferation and maturation [33].

In this study, the function of T cells remained anergic after dexamethasone removal. Giles et al. have shown that dexamethasone upregulates CTLA-4 molecules on the T cells and blocks CD28-mediated cell cycle entry and differentiation [30] suggesting that the absence of CD28/CD80 or CD28/CD86 costimulatory signaling induces an anergic state in T cells. Moreover, the T cell receptor complex is disrupted after binding the glucocorticoid to the corresponding receptor [34]. Since Tokunaga et al. have shown that early corticosteroids in malignant melanoma patients treated with CTLA-4 inhibitors shortened the overall survival [35], the CTLA-4 blockade alone is not sufficient to overcome steroid-mediated immunosuppression. As Wayne et al. have reported [36], the T cell exhaustion markers (PD-1, LAG3, and TIM3) did not change with steroid treatment in this study, indicating that PD-1 blockade cannot overcome steroid-induced immunosuppression. In addition to the lack of costimulatory signaling, the corticosteroids cause T cell dysfunction by suppressing IL-2 production [19]. Because IL-2 is an essential cytokine that activates the antitumor activity of cytotoxic T cells and NK cells [37], we used IL-2 as an adjuvant to overcome steroid-induced immunosuppression. The supplementation with IL-2 was efficient in recovering the inhibited antitumor T cells by steroids in vitro and in vivo. Regardless of steroids, IL-2 is considered as a promising immunoadjuvant in various types of immunotherapy, including peptide vaccines [38,39]. Although the safety of IL-2 administration in humans has been confirmed in clinical practice for treating patients with melanoma and renal cell carcinoma, IL-2 is rapidly degraded in vivo. To increase the half-life of IL-2, IL-2 can be combined with an anti-IL-2 antibody to produce IL-2 Cx that augments tumor-reactive T cell responses [38,39] and efficiency of ICIs [40,41]. Since we have shown that steroids inhibit the stimulation of T cells through the MHC-peptide-T cell receptor complex, further studies are required to elucidate whether the pre-activated T cells are suppressed by steroids, and the appropriate dose or timing to spare the negative effects of corticosteroids on ICIs in a larger cohort of patients. The maximum recommended dose of dexamethasone is 20 mg for antiemetic as well as in the treatment for immune-related adverse effects or auto-immune diseases. The maximum observed concentration of 20 mg dexamethasone is 0.26 ng/ml [42], which is almost similar to the dose sufficient to inhibit antitumor T cell responses in this study (0.3 ng/ml, Fig. 4). Thus, we believe that the dexamethasone dose in our in vitro experiments is relevant to the clinical setting. The dose used in our mouse models (1 mg/kg) was relatively higher than the dose used for antiemetic in human. However, it would be difficult to directly compare the intravenously administered dose in human with the intraperitoneally administered dose in mice since the bioavailability of drug is different between intravenous and intraperitoneal route due to the first pass metabolism [43]. Further studies to examine the different doses of steroid with PD-1 blockade are required. As dexamethasone is more potent and long-acting than other corticosteroids, immunosuppression among the types of steroids should also be examined. A limitation of the mouse model in study is that the T cell epitope from mouse HNSCC has not been identified. To study the influence of steroid in antigen-specific T cell responses, we used human EGFR-reactive HTLs. Fortunately, steroid decreased T cells in both mouse and human models. The establishment of a tumor antigen-specific T cell model in mouse HNSCC is required to further examine the antitumor T cell responses in the future.
Conclusions

Dexamethasone decreased the antitumor effect of combination therapy with anti-PD-1 Ab and CDDP in an HNSCC mouse model by reducing the T cell proliferation and suppressing memory T cells. In vitro assessment using antigen-specific T cells showed that dexamethasone induced apoptosis, decreased proliferation, and reduced tumor cytotoxicity. Notably, IL-2 or IL-2 Cx restored steroid-induced immunosuppression of T cells by restoring the proliferation and function of T cells in vitro and in vivo. These results suggest that the use of steroids should be avoided unless necessary during immunotherapy in HNSCC patients, and IL-2 Cx might be a promising adjuvant to recover immunosuppression with steroids.

CRediT authorship contribution statement

Michihiwa Kono: Funding acquisition, Formal analysis, Data curation, Conceptualization, Visualization, Supervision, Writing – original draft. Hideyuki Yamaoki: Funding acquisition, Formal analysis, Data curation. Hiroki Komada: Funding acquisition, Formal analysis, Data curation. Takumi Kumai: Funding acquisition, Formal analysis, Data curation. Methodology, Conceptualization, Visualization, Supervision, Writing – original draft, Writing – review & editing. Ryusuke Hayashi: Funding acquisition, Formal analysis, Data curation. Risa Wakisaka: Funding acquisition, Formal analysis, Data curation. Ryusuke Sato: Formal analysis. Kenzo Ohara: Resources. Miki Takahara: Formal analysis. Akihito Katada: Formal analysis. Tatsuya Hayashi: Resources, Methodology. Yasuaki Harabuchi: Methodology, Writing – review & editing.

Declaration of Competing Interest

None declared.

Funding

This work was supported by JSPS KAKENHI Grant Number 20K09724.

Availability of data and material

All data relevant to the study are included in the article or uploaded as supplementary information.

Ethics approval and consent to participate, Consent for publication

All experiments were approved by the institutional ethics committee on the Asahikawa Medical University (#16217). The study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Acknowledgments

The authors also thank Dr. Hajime Kamada (Hokuto Social Medical Corporation) for his excellent suggestions for the manuscript.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.tranon.2022.101358.

References

[1] J.D. Moy, J.M. Moskovitz, R.L. Ferris, Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma, Eur. J. Cancer 76 (2017) 152-166.
[2] J. Bernier, C. Domene, M. Ozaslan, K. Matuszewka, J.L. Lefebvre, R.H. Greiner, J. Girah, P. Maingon, F. Rolland, M. Bolla, F. Cognetti, J. Bourhis, A. Kirkpatrick, M. van der Globbeke, European Organization for Research and Treatment of Cancer Radiation Therapy Oncology Group, Radiation Therapy to the neck: results of RTOG 0617, J. Clin. Oncol. 31 (2013) 1937-1944.
[3] J.S. Cooper, T.F. Pajak, A.A. Forastiere, J. Jacobs, B.H. Campbell, S.B. Saxman, J. A. Kish, H.E. Kim, A.J. Cmelak, M. Rotman, M. Machay, J.F. Esmly, K.S. Chao, C. J. Schultz, N. Lee, K.K. Fu, Radiation Therapy Oncology Group 9501/Intergroup, Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck, N. Engl. J. Med. 350 (2004) 1937-1944.
[4] R.L. Ferris, G. Blumenschein, J. Fayette, J. Guigay, A.D. Colevas, L. Licitra, K. Harrington, S. Kasper, E.E. Vokes, C. Even, F. Worden, N.F. Saba, I.C. Lisgates Donor, R. Radda, T. Borde, N. Kiyota, M. Tahara, M. Monga, M. Lynch, W. J. Geene, J. Kopit, J.W. Shaw, M.L. Gillison, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N. Engl. J. Med. 375 (2016) 1856-1867.
[5] T.Y. Seiwert, B. Burtness, R. Mehrin, J. Weiss, R. Berger, J.P. Eder, K. Heath, T. McLanahan, J. Lancefred, C. Gause, J.D. Chen, L.Q. Chow, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol. 17 (2016) 956-965.
[6] S.I. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Somsan, M.B. Atkins, P.D. Leming, D.R. Spigel, S. J. Antonia, L. Horn, C.G. Drake, D.M. Pardoll, L. Shen, W.H. Sharram, R. A. Anders, J.M. Taube, T.L. McMillner, H. Xu, A.J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G.D. Kollia, A. Gupta, J.M. Wigginton, M. Smol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med. 366 (2012) 2443-2454.
[7] O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefferd, J.D. Woldchok, P. Hervey, R.W. Joseph, S. Green, R. Driona, A. Finet, H. Watanabe, A. Pesando, R. Bo, C. Guo, Z. Sun, L. Zhang, K. Sundareshan, M. Kornelak, J. Assouline, A. Libeskind, C. Chen, J. Gao, N. Angel, G. Cabanillas, M. Kowalski, J. Feng, J. Xie, M. Hwu, M. Smol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med. 350 (2004) 1937-1944.
[8] L. Gandhi, D. Rodriguez-Abreu, D. Ciardiello, L. Meropol, D. Cullinan, O. Hanash, D.J. Forastiere, J. Machtay, J. Urba, J. Starling, J. Lederman, J. Bartlett, M. Antonia, A. Lencioni, A. Ferrara, S. Lochen, J. Sharram, E. Ertl, J. Radda, C. Robert, R. George, M. Zhou, J. Kornelak, J. Feng, J. Xie, M. Hwu, M. Smol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med. 366 (2012) 2443-2454.
[9] C.H. June, J.T. Warshauer, J.A. Bluestone, Is autoimmunity the Achilles heel of cancer immunotherapy? Nat. Med. 23 (2017) 540-547.
[10] L. Hofmann, A. Forscher, C. Loquai, S.M. Goldinger, L. Zimmer, S. Ugurel, M. I. Schmidgen, R. Guttmann, J.S. Uitak, D. Goppen, J.C. Hasel, F. Meier, J. K. Tietze, I. Thomas, C. Weishaupt, M. Leverkus, R. Wahl, U. Dietrich, C. Garbe, M. C. Kirchberger, T. Eigentler, C. Berking, A. Gesierich, A.M. Ackrhardt, D. Schadendorf, G. Schulier, R. Dummer, L.M. Heiznerling, Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy, Eur. J. Cancer 60 (2016) 190-209.
[11] C.F. Friedman, T.A. Proverbs-Singh, M.A. Postow, Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review, JAMA Oncol. 2 (2016) 1346-1353.
[12] K.C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Aucin, A. Ni, G. Martinez-Bernal, R. Ferrara, W.V. Lai, L.E.L. Hendriks, J.K. Sabari, C. Carmelina, J.A. Plisokowski, D. Halpenny, J.E. Chait, M.W. Gallinger, D. Hellin, D. Helling, D. Bunn, J.C. Topalian, Early use of steroids increases immune cells and impairs immunotherapy efficacy, ESOMO Open 4 (2019), e000477.
[13] T.M. Dela Corte, P. Morgillo, Early use of steroids affects immune cells and impairs immunotherapy efficacy, ESOMO Open 4 (2019), e000477.
[14] F. Gafa, G. Galli, M. Poggi, G.G. Ruso, C. Proto, M. Imbriaco, R. Ferrara, N. Zilembo, M. Ganzinelli, A. Sica, V. Torri, M.P. Colombo, C. Vernieri, A. Balsari, F. de Braud, M.C. Garassino, D. Signorelli, Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors, ESOMO Open 4 (2019), e000457.
[15] A. D’Souza, P. Hari, M. Pasquini, T. Braun, B. Johnson, S. Lundy, D. Couriel, M. Hamadani, J. Magenau, B. Dhakal, N.N. Shah, M. Riwes, B. Parkin, P. Reddy, A. Pawarode, A Phase 2 study of pembrolizumab during lymphodepletion after autologous hematopoietic cell transplantation for multiple myeloma, Biol. Blood Marrow Transplant. 25 (2019) 1492-1497.
B. Shankar, J. Zhang, A.R. Naqash, P.M. Forde, J.L. Feliciano, K.A. Marrone, D.J.S. Weber, F.S. Hodi, J.D. Wolchok, S.L. Topalian, D. Schadendorf, J. Larkin, D.J. Pinato, A. Kaseb, Y. Wang, A. Saeed, D. Szafron, T. Jun, S. Dharmapuri, A. D.B. Keskin, A.J. Anandappa, J. Sun, I. Tirosh, N.D. Mathewson, S. Li, G. Oliveira, P. Tallon de Lara, V. Cecconi, S. Hibbrunner, H. Yagita, M. Freni, B. Ode, I. Opitz, B. Vrugt, W. Weder, P. Stolzmann, E. Felley-Bosco, R.A. Stahel, V. Tischler, B. Ricciuti, S.E. Dahlberg, A. Adeni, L.M. Sholl, M. Nishino, M.M. Awad, Immune J. B. Iorgulescu, P.C. Gokhale, M.C. Speranza, B.K. Eschle, M.J. Poitras, M. C. Libert, L. Dejager, How steroids steer T cells, Cell Rep. 7 (2014) 938–949.

M. Kono et al.

M. Ettinger, C.L. Hann, J.R. Brahmer, B. Ricciuti, D. Owen, Y. Toi, P. Walker, A. Adeni, L.M. Sholl, M. Nishino, M.M. Awad, Immunotherapy 37 (2019) 1927–1934.

J. B. Iorgulescu, P.C. Gokhale, M.S. Speranza, B.K. Eschle, M.J. Poitras, M. C. Libert, L. Dejager, How steroids steer T cells, Cell Rep. 7 (2014) 938–949.

M. Kono et al.

M. Ettinger, C.L. Hann, J.R. Brahmer, B. Ricciuti, D. Owen, Y. Toi, P. Walker, G. nivolumab monotherapy: a pooled analysis of patients with advanced melanoma, M. Sznol, G.V. Long, H. Li, I.M. Waxman, J. Jiang, C. Robert, Safety profile of (2020) e000726.

T. Tran, K.J. Redmond, H. Brem, D.M. Pardoll, L.R. Kleinberg, M. Lim, Contrasting histologies located within or outside the central nervous system, Oncoimmunology 7 (2018), e1500108.

E.J. Wherry, V. Teichgraber, T.C. Becker, D. Matouso, S.M. Kaech, R. Antia, U. H. von Andrian, R. Ahmed, Lineage relationship and protective immunity of memory CD8 T cell subsets, Nat. Immunol. 4 (2003) 225–234.

A.J. Giles, M.N.D. Hutchinson, H.M. Sonnenman, J. Jung, P.E. Fecci, N.M. Ratnam, W. Zhang, H. Song, R. Bailey, D. Davis, C.M. Reid, D.M. Park, M.R. Gilbert, Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy, J. Immunother. Cancer 6 (2018) 51.

T. Kumai, K. Okawa, N. Aoki, S. Kimura, Y. Harabuchi, H. Kobayashi, Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid, Head Neck 38 (2016) 410–416.

A. Sica, A. Mantovani, Macrophage plasticity and polarization: in vivo veritas, J. Clin. Invest. 122 (2012) 787–795.

I. Szatmari, L. Nagy, Nuclear receptor signaling in dendritic cells connects lipid, the genome and immune function, EMBO J. 27 (2008) 2353–2362.

M. Lowenberg, A.P. Verhaar, G.R. van den Brink, D.W. Hommes, Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression, Trends Mol. Med. 13 (2007) 158–163.

A. Tokunaga, D. Sugiyama, Y. Maeda, A.B. Warner, K.S. Panaigays, S. Itô, Y. Togashi, C. Sakai, J.D. Wolchok, H. Nishikawa, Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids, J. Exp. Med. 216 (2019) 2701–2713.

W.J. Aston, D.E. Hope, A.M. Cook, L. Boon, I. Dick, A.K. Nowak, R.A. Lake, W. J. Lesterhuis, Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment, Oncoimmunology 8 (2019), e1641390.

R. Spolski, P. Li, W.J. Leonard, Biology and regulation of IL-2: from molecular mechanisms to human therapy, Nat. Rev. Immunol. 18 (2018) 648–658.

H. Sultan, T. Kumai, V.I. Fesenkova, A.E. Fan, J. Wu, H.J. Cho, H. Kobayashi, Y. Harabuchi, E. Celis, Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition, Cancer Immunol. Res. 6 (2018) 617–627.

G. Verdziel, K. Marquardt, C.D. Suh, L.A. Sherman, Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16683–16688.

J.M. Deresp, Y. Deng, S.L. Pandeswara, A.S. Padron, R.M. Reyes, X. Zhang, J. Mendez, A. Liu, C.A. Clark, W. Chen, J.R. Conejo-Garcia, V. Hurez, H. Gupta, T. J. Curiel, CD122-selective IL2 complexes reduce immunosuppression, promote treg fragility, and sensitize tumor response to PD-L1 blockade, Cancer Res. 80 (2020) 5063–5075.

R.M. Reyes, Y. Deng, Z. Zhang, N. Ji, N. Mukherjee, K. Wheeler, H.B. Gupta, A. S. Padron, A. Kancharia, C. Zhang, M. Garcia, A.V.R. Kornepati, O. Boyman, J. R. Conejo-Garcia, R.S. Swatek, T.J. Curiel, CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from alphaPD-L1 and include tissue-selective gammaldera T cell activation, J. Immunother. Cancer 9 (2021) e02051.

Q. Bashir, M. Acosta, Comparative safety, bioavailability, and pharmacokinetics of oral dexamethasone, 4-mg and 20-mg tablets, in healthy volunteers under fasting conditions: a randomized open-label, 3-week crossover study, Clin. Pharmacol. 204 (2020) 768–773.

A. Al Shoyaib, S.R. Archie, V.T. Karamyan, Intraperitoneal route of drug administration: should it be used in experimental animal studies? Pharm. Res. 37 (2019) 12.